Key facts
- It has raised $8.3M; the latest was Early Stage VC ($8.3M) in Jan 2025.
- Notable investors include i&i Prague.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Adalid Sciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Adalid Sciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Adalid Sciences
Developer of novel lipid nanoparticles intended for effective drug delivery. The company specializes in developing lipid nanoparticle delivery systems for nucleic acid therapeutics to enhance the stability and bioavailability of drugs, improving their therapeutic efficacy while minimizing potential side effects, enabling industries to improve delivery systems for genomic medicine to ensure optimal performance, safety, and efficacy.
- Sector
- Healthcare
- HQ
- Prague, Czech Republic
- Founded
- 2024
- Employees
- 12
- Website
- adalidsciences.com/
- Ownership
- Privately Held (backing)
Adalid Sciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Adalid Sciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Adalid Sciences in its N-PORT filings yet. We sweep new filings monthly.